Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 6
2005 2
2006 5
2007 6
2008 4
2009 3
2010 1
2011 3
2012 3
2013 9
2014 11
2015 4
2016 4
2017 8
2018 2
2019 4
2020 7
2021 17
2022 10
2023 10
2024 12
2025 18
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv F, Zhang Q, Sun X, Liu L, Huang Y, Yang H, Gao S, He C, Yang W, Li W, Yu D, Yang Y, Cheng Y, Qian Z, Xiang Y, Guo Q, Xu B, Song Y, Zhang L, Lin L, Shen J, Yan F, Liu H, Zhang D, Wang J, Zhou M, Zhu X, Zhang W, Zhao W, Feng R, Zhang X, Jin J, Zhong M, Zhang M, Wang J, Jing H, Wang Z, Zhao H, Zhu J. Li Z, et al. Among authors: zhang d. J Immunother Cancer. 2024 Oct 24;12(10):e008895. doi: 10.1136/jitc-2024-008895. J Immunother Cancer. 2024. PMID: 39455094 Free PMC article. Clinical Trial.
Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.
Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X. Su RY, et al. Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):106-112. doi: 10.1016/j.hbpd.2021.09.001. Epub 2021 Sep 8. Hepatobiliary Pancreat Dis Int. 2022. PMID: 34583911
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years.
Yu B, Wang H, Li G, Sun J, Luo H, Yang M, Zhang Y, Liu R, Cheng M, Zhang S, Li G, Wang L, Qian G, Zhang D, Li S, Kan Q, Jiang J, Ren Z. Yu B, et al. Among authors: zhang d. Acta Pharm Sin B. 2025 Mar;15(3):1333-1343. doi: 10.1016/j.apsb.2024.12.032. Epub 2024 Dec 31. Acta Pharm Sin B. 2025. PMID: 40370553 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.
Wang H, Cui G, Cheng M, Aji T, Li G, Hu X, Li G, Zhang S, Zhang Y, Diao L, Li P, Wang L, Yuan Y, Qian G, Zhang R, Jin X, Wang J, Luo H, Zhang D, Wang M, Li S, Song Z, Yang M, Su G, Sun R, Chang J, Yu Z, Ren Z. Wang H, et al. Among authors: zhang d. Signal Transduct Target Ther. 2025 Jan 17;10(1):30. doi: 10.1038/s41392-025-02126-w. Signal Transduct Target Ther. 2025. PMID: 39819859 Free PMC article.
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID-19: A Multicenter, Retrospective, Real-World Study.
Sun R, Wang H, Sun J, Yang M, Zhang S, Hu X, Yu B, Song Z, Han N, Luo H, Cheng M, Li G, Li G, Yuan Y, Liang L, Zhang Y, Zhang D, Li S, Kan Q, Liang H, Ren Z. Sun R, et al. Among authors: zhang d. Adv Sci (Weinh). 2025 Apr;12(13):e2404450. doi: 10.1002/advs.202404450. Epub 2025 Feb 11. Adv Sci (Weinh). 2025. PMID: 39932451 Free PMC article.
151 results